Healthcare
Live Price
Offline$24.23
+0.00% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Biotest AG (BTTAY) is a Healthcare stock with a market cap of $943.03M. The stock last traded around $24.23. Baseline metrics include revenue growth of +6.1%, EPS growth of -77.8%, a dividend yield of 0.1%. What stands out right now is revenue +6.1%, EPS -77.8%, free cash flow +189.2% with operating margin 0.1% and ROIC 0.0%. The dividend is present but secondary, with a yield around 0.1%. Valuation sits in the middle of the pack at price/sales 4.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines BTTAY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BTTAY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BTTAY Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BTTAY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$484.2M
-6.1% YoY
FY Net Income
-$31.4M
+50.4% YoY
Free Cash Flow
-$43.7M
-378.3% YoY
Revenue Growth
+6.1%
EPS Growth
-77.8%
Gross Margin
20.4%
Net Margin
-7.6%
Income statement
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 726M | 685M | 516M | 516M | 484M |
| Gross Profit | 224M | 280M | 125M | 81M | 130M |
| Operating Income | 95M | 144M | -17M | -47M | -1M |
| EBITDA | 120M | 182M | 25M | -18M | 14M |
| Net Income | 26M | 127M | -32M | -63M | -31M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 108M | 119M | 117M | 104M | 71M |
| Total Assets | 1.4B | 1.4B | 1.2B | 1.1B | 1.1B |
| Total Liabilities | 903M | 912M | 832M | 724M | 690M |
| Shareholder Equity | 531M | 499M | 371M | 380M | 442M |
| Total Debt | 597M | 690M | 574M | 496M | 469M |
| Net Debt | 489M | 571M | 458M | 392M | 398M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
17M
-149.3% YoY
Capital Expenditures
27M
-48.4% YoY
Free Cash Flow
44M
-378.3% YoY
Key ratios
Gross Margin
20.4%
Operating Margin
0.1%
Net Margin
-7.6%
ROE
-4.8%
Debt / Equity
1.31x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.